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Subcutaneous phaeohyphomycosis typically affects immunocompetent individuals following traumatic inoculation.
Severe or disseminated infection can occur in CARD9 deficiency or after transplantation, but the mechanisms protecting
against phaeohyphomycosis remain unclear. We evaluated a patient with progressive, refractory Corynespora cassiicola
phaeohyphomycosis and found that he carried biallelic deleterious mutations in CLEC7A encoding the CARD9-coupled,
β-glucan–binding receptor, Dectin-1. The patient’s PBMCs failed to produce TNF-α and IL-1β in response to β-glucan and/or
C. cassiicola. To confirm the cellular and molecular requirements for immunity against C. cassiicola, we developed a mouse
model of this infection. Mouse macrophages required Dectin-1 and CARD9 for IL-1β and TNF-α production, which enhanced
fungal killing in an interdependent manner. Deficiency of either Dectin-1 or CARD9 was associated with more severe fungal
disease, recapitulating the human observation. Because these data implicated impaired Dectin-1 responses in susceptibility
to phaeohyphomycosis, we evaluated 17 additional unrelated patients with severe forms of the infection. We found that
12 out of 17 carried deleterious CLEC7A mutations associated with an altered Dectin-1 extracellular C-terminal domain and
impaired Dectin-1–dependent cytokine production. Thus, we show that Dectin-1 and CARD9 promote protective TNF-α– and
IL-1β–mediated macrophage defense against C. cassiicola. More broadly, we demonstrate that human Dectin-1 deficiency may
contribute to susceptibility to severe phaeohyphomycosis by certain dematiaceous fungi.

Authorship note: RAD and JVD contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Copyright: © 2022, Drummond et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Submitted: February 18, 2022; Accepted: September 21, 2022; Published: November 15, 2022.
Reference information: J Clin Invest. 2022;132(22):e159348. https://doi.org/10.1172/JCI159348.

1

RESEARCH ARTICLE

Introduction

The Journal of Clinical Investigation  

Phaeohyphomycosis is an invasive fungal infection caused by
dematiaceous fungi, which are characterized by melanin production and filamentous growth. Phaeohyphomycosis typically
affects the subcutaneous tissues following traumatic inoculation
and is treatable with antifungal therapy and/or surgical resection.
Phaeohyphomycosis may also manifest as cerebral or disseminated disease in immunosuppressed patients or, infrequently,
in putatively immunocompetent individuals, and its prognosis is
usually poor (1, 2). Better understanding of the pathogenesis of
phaeohyphomycosis may improve the management and outcome
of affected patients.
Phaeohyphomycosis has been reported in CARD9 deficiency (3–5), a primary immunodeficiency disorder characterized by severe fungal infections that involve predominantly the
oral mucosa, subcutaneous tissues, and brain (5–13). CARD9
deficiency is caused by biallelic loss-of-function mutations
in CARD9, which encodes an adaptor protein that relays fungus-sensing signals by multiple C-type lectin receptors (CLRs),
such as Dectin-1 (6, 10, 14). Mechanistically, CARD9 mediates
neutrophil effector function and recruitment to the fungus-infected brain, via IL-1β and CXCL1 production by brain-resident phagocytes (15–17). The CARD9-dependent mechanisms
of antifungal protection within subcutaneous tissues remain
poorly defined, with recent studies indicating that CARD9 may
promote neutrophil recruitment to that tissue (3) and IL-17 production (18). CARD9-coupled CLRs, such as Dectin-1, have also
been implicated in activating protective antifungal immune
responses in humans. For example, the deleterious mutation
p.Y238* in CLEC7A, which encodes Dectin-1, has been previously associated with familial vaginal yeast infections and onychomycosis, which was linked to impaired Dectin-1–dependent
production of proinflammatory cytokines, including IL-17, in
response to the Dectin-1 ligand, β-glucan, and Candida yeast
cells (19). In addition, the presence of p.Y238* in either donors
or recipients of allogeneic hematopoietic stem cell transplantation has been associated with the development of invasive pulmonary aspergillosis (20).
We describe an index patient with severe phaeohyphomycosis caused by Corynespora cassiicola, a dematiaceous fungus
of plants known to cause life-threatening infections in CARD9
deficiency (4, 21). Our patient had biallelic deleterious mutations in CLEC7A, which encodes the CARD9-coupled receptor,
Dectin-1. We show that Dectin-1 is critical for IL-1β and TNF-α
production against this fungus by human immune cells. Both
Dectin-1 and CARD9 deficiencies heightened susceptibility
in a mouse model of subcutaneous C. cassiicola infection. Protection involved Dectin-1– and CARD9-dependent IL-1β and
TNF-α production, which enhanced macrophage fungal killing.
We also evaluated 17 additional unrelated patients with severe
phaeohyphomycosis and found that 12 out of 17 had deleterious CLEC7A mutations, which were associated with an altered
Dectin-1 extracellular, β-glucan–binding, C-terminal domain,
and impaired Dectin-1–dependent cytokine production. Thus,
human Dectin-1 deficiency may contribute to susceptibility
to severe phaeohyphomycosis by certain dematiaceous fungi,
likely following traumatic inoculation.
2

Results

Clinical presentation. A 64-year-old African American male living
in Louisiana, United States, first presented to a local hospital in
1984 (at age 27) with a nonhealing growth on his nose following
an injury he sustained while working in construction (22). Biopsy
revealed mixed yeast and melanin-pigmented fungal filaments,
leading to the diagnosis of phaeohyphomycosis, although identification at the fungal species level was not possible. The patient
had a normal peripheral white blood cell count and differential
and unremarkable chemistries. He was treated with oral ketoconazole (200 mg/day) for 9 months with some improvement, but
the infection recurred within 6 weeks of stopping therapy. Three
additional months of ketoconazole failed to improve the nasal
lesion, prompting a dose increase to 400 mg for 4 more months,
which led to marked improvement (22). However, the patient
experienced several infection relapses over the subsequent 18
years. In 2004 (at age 47), he presented to an outside hospital with
severe facial ulcerations. Despite escalation of antifungal therapy
to itraconazole, amphotericin B, and caspofungin, and multiple
debridements, the infection progressed, and the patient was transferred to the NIH Clinical Center. He had no other medical conditions and no prior history of infections, including mucocutaneous
candidiasis, dermatophytosis, or onychomycosis. His family history was noncontributory. Physical examination revealed extensive
ulcerative and necrotic facial lesions (Figure 1A). Laboratory studies revealed leukocytosis with a white blood cell count of 30,000
cells/μL, of which 89% were neutrophils, 2.8% monocytes, 7.7%
lymphocytes, and 0.5% eosinophils. Serum immunoglobulin
(including IgE) levels were within normal limits. Biopsy of the
facial lesions demonstrated granulomatous inflammation with
plasma cells, few neutrophils, and rare eosinophils, with fungal
elements engulfed, but not destroyed, within macrophages (Figure 1B and Supplemental Figure 1; supplemental material available
online with this article; https://doi.org/10.1172/JCI159348DS1).
Fungi grew as sterile mycelia and were identified molecularly
as C. cassiicola (Supplemental Figure 2). The minimal inhibitory
concentrations for amphotericin B, itraconazole, posaconazole,
caspofungin, and terbinafine were low at 0.125, 0.06, 0.06, 0.125,
and 0.06 μg/mL, respectively. The facial lesions were extensively
debrided. While receiving posaconazole and caspofungin, a cerebellar lesion was noted, and biopsy demonstrated neutrophilic
microabscesses and granulomatous inflammation and fungal elements. 5-Flucytosine, terbinafine, and subcutaneous IFN-γ were
added and the patient eventually improved. Multiple reconstructive surgeries and skin grafting procedures were performed over
the subsequent year. The patient has not developed any recurrences over the past 16 years while receiving itraconazole secondary
prophylaxis (Figure 1A).
Identification of biallelic deleterious CLEC7A mutations. A dihydrorhodamine test revealed normal phagocyte respiratory burst.
We performed whole-exome sequencing to search for genes
underlying human fungal susceptibility (23). We identified biallelic mutations in CLEC7A (Figure 1C and Table 1), which encodes
Dectin-1. One allele contained the c.714T>G (p.Y238*) nonsense
mutation (combined annotation-dependent depletion [CADD]
score 36; https://cadd.gs.washington.edu/score. Accessed January, 2021.) (19). When in homozygosity or heterozygosity, p.Y238*
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Figure 1. A Dectin-1–deficient patient with
severe Corynespora cassiicola phaeohyphomycosis. (A) Photographs of the index patient
at presentation at the NIH in 2004 (left) and
following antifungal treatment and secondary
prophylaxis in 2018 (right). (B) Grocott’s methenamine silver–stained (GMS-stained, left) and
hematoxylin and eosin–stained (H&E-stained,
right) section of soft tissue biopsy demonstrating C. cassiicola being engulfed but not
destroyed in macrophages (black arrowheads)
within granulomas (×100 magnification shown
in Supplemental Figure 1). Scale bars: 20 μm.
(C) Chromatograms from CLEC7A sequencing
on healthy control and our patient, over the site
of mutation in each allele. (D) Representative
FACS histograms showing Dectin-1 surface
expression in our patient and 2 healthy control
patients. Histograms were gated on CD14+
monocytes isolated from peripheral blood. (E)
Representative protein immunoblot images of
Dectin-1 expression in PBMCs from our patient
and a healthy volunteer (HV). β-Actin was used
as loading control. (F) TNF-α production by
PBMCs after 48 hours of stimulation with either
purified particulate β-glucan or α-mannan. Each
data point represents an individual well; at least
2 separate blood draws were analyzed in the
Dectin-1–deficient patient (each tested in 2–3
technical replicates) and compared to 2 different
healthy controls (each tested in 2–3 technical
replicates). A single blood draw from each of
the CARD9-deficient patients was analyzed in
3–5 technical replicates. Data in panel F were
analyzed by 2-way ANOVA with Bonferroni’s
correction. ***P < 0.005, ****P < 0.0001. NS,
not significant. (G) Photograph of a previously
reported CARD9-deficient patient (CARD9.02)
(21) at presentation at the NIH (age 12). (H)
Volume rendering of computed tomography
data of patient CARD9.02 at age 12 emphasizing bone, which reveals erosions of the frontal
bone (black arrows) and loss of maxillofacial
structures (white arrow), including the hard
palate, resulting in a common oronasal cavity.
(I) Parasagittal T1-weighted magnetic resonance
imaging of patient CARD9.02 at age 12 obtained
following i.v. gadolinium-based contrast agent
administration, which reveals epidural abscess
with adjacent cerebritis (black arrow) and tissue
loss (white arrow) resulting in a common cavity
encompassing the nasopharynx, oropharynx,
nasal cavity, oral cavity, and portions of the
paranasal sinuses. (J) GMS- (upper) and H&Estained (lower) section of soft tissue biopsy
demonstrating granulomatous inflammation
with C. cassiicola engulfed within macrophages
(accompanying images from brain biopsy shown
in Supplemental Figure 4). Both images are from
consecutive cuts of the same biopsy sample.
Scale bars: 20 μm.

has been associated with impaired Dectin-1–dependent cellular responses (19, 20, 24, 25). The other allele had the missense
mutation c.668T>G (p.I223S), which is predicted to be deleterious
(PolyPhen-2 score 1.0 [http://genetics.bwh.harvard.edu/pph2/.

Accessed January, 2021]; CADD score 23.8). The p.Y238* and
p.I223S mutations have population allelic frequencies of 6.0% and
0.33%, respectively (gnomAD v2.1.1; https://gnomad.broadinstitute.org/. Accessed May, 2021).
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Table 1. Demographic, clinical, and genetic characteristics of patients with severe forms of phaeohyphomycosis described in this study
Patient
no.

Age at
diagnosis
in years

Sex

Race/Ethnicity

CLEC7A variantA
(protein variant,
CADD score)

CARD9 variantA
(protein variant,
CADD score)

Agent of
phaeohyphomycosis

Localization
of infection

1 (Index)

27

M

Black/non-Hispanic

Not identified

Corynespora cassiicola

Skin, brain

None

2

67

M

White/non-Hispanic

Not identified

None

32

M

Black/non-Hispanic

Not identified

Cladophialophora
bantiana
Curvularia

Brain

3

Brain, lung

None

4

39

F

Black/non-Hispanic

Not identified

Bipolaris

67

M

White/non-Hispanic

Not identified

Fonsecaea

Brain, liver,
biliary tree
Brain

None

5
6

51

F

White/non-Hispanic

Not identified

Not specified

Brain

None

7

47

M

White/non-Hispanic

Not identified

None

53

M

White/non-Hispanic

Brain

None

9

66

M

White/non-Hispanic

Brain

None

10

22

M

Black/non-Hispanic

Not identified

Cladiophialophora
bantiana
Cladophialophora
bantiana
Cladophialophora
bantiana
Bipolaris

Brain

8

Brain, lung

None

63

11

35

M

Black/non-Hispanic

Not identified

Curvularia geniculata

Brain

None

64

12

42

M

Black/non-Hispanic

Not identified

Curvularia

Brain, sinus

None

13

64

F

White/non-Hispanic

Not identified

None

50

F

Black/non-Hispanic

Cladophialophora
bantiana
Curvularia

Brain

14

Compound heterozygous for
c.714T>G (p.Tyr238Ter, 36) and
c.668T>G (p.Ile223Ser, 23.8)
Homozygous for c.714T>G
(p.Tyr238Ter, 36)
Homozygous for c.714T>G
(p.Tyr238Ter, 36)
Heterozygous for c.714T>G
(p.Tyr238Ter, 36)
Heterozygous for c.714T>G
(p.Tyr238Ter, 36)
Heterozygous for c.714T>G
(p.Tyr238Ter, 36)
Heterozygous for c.714T>G
(p.Tyr238Ter, 36)
Heterozygous for c.714T>G
(p.Tyr238Ter, 36)
Heterozygous for c.714T>G
(p.Tyr238Ter, 36)
Homozygous for c.668T>G
(p.Ile223Ser, 24)
Homozygous for c.668T>G
(p.Ile223Ser, 24)
Heterozygous for c.668T>G
(p.Ile223Ser, 23.8)
Heterozygous for c.547C>T
(p.Leu183Phe, 25)
Not identified

Brain, sinus

None

15

13

M

Black/non-Hispanic

Not identified

Curvularia

Brain, sinus

None

16

30

F

Asian/non-Hispanic

Not identified

Brain

None

17
18

7
24

M
M

Black/non-Hispanic
White/non-Hispanic

Not identified
Not identified

Cladophialophora
bantiana
Not specified
Cladophialophora
bantiana

Brain
Brain

None
None

Not identified
Not identified

Heterozygous
for c.209G>A
(p.Arg70Gln, 23.5)
Heterozygous
for c.901A>G
(p.Ile301Val, 23.2)
Not identified
Not identified
Heterozygous
for c.175C>T
(p.Arg59Trp, 26.5)

History of Reference
other
infections

61

None

62

65

Variants with CADD scores >20.

A

We examined the consequences of these CLEC7A mutations
for Dectin-1 expression. The patient’s monocytes had significantly reduced Dectin-1 surface expression by flow cytometry with
an antibody that recognizes the extracellular, β-glucan–binding,
C-terminal domain where the Dectin-1 mutations reside (Figure
1D and Supplemental Figure 3). By contrast, Dectin-1 expression
in PBMCs was normal by immunoblot analysis with an antibody
that recognizes the extracellular stalk region of Dectin-1, which
is unaffected by the patient’s CLEC7A mutations (Figure 1E and
Supplemental Figure 3; see complete unedited blots in the supplemental material). Normal Dectin-1 expression by immunoblot
was verified with the antibody that recognizes the extracellular
stalk region in HEK293 cells transfected with p.Y238* (Supplemental Figure 4; see complete unedited blots in the supplemen4

tal material). Therefore, p.Y238* does not decrease Dectin-1
protein production but it alters its extracellular β-glucan–binding
C-terminal domain. To understand the functional consequences
of these mutations, we stimulated PBMCs from the patient and
healthy volunteers with purified β-glucan (a Dectin-1 ligand;
ref. 26) or α-mannan (a Dectin-2 ligand; ref. 27) and measured
TNF-α production, since phaeohyphomycosis is a reported complication of TNF-α–targeted biologics (28). The patient’s cells
had blunted TNF-α production in response to β-glucan but not in
response to α-mannan, which does not bind Dectin-1 (Figure 1F).
As controls, PBMCs from 2 CARD9-deficient patients, one with
invasive candidiasis (CARD9.1; ref. 16) and another with C. cassiicola phaeohyphomycosis (CARD9.2; ref. 21), did not respond
to either β-glucan or α-mannan (Figure 1F).
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Figure 2. Dectin-1 binds to Corynespora cassiicola and contributes to proinflammatory cytokine production in response
to the fungus. (A) Representative images of staining for Dectin-1–binding pathogen-associated molecular patterns using
soluble Dectin-1 (Dectin-1 recognition domain fused with human Fc fragment) on C. cassiicola. Anti–human Fc–PE (visualized
in DS-Red channel) was used as the secondary antibody or was used alone as negative control. Scale bars: 50 μm (upper panel)
and 25 μm (enlarged images of C. cassiicola overlay in lower panel). (B) Cytokine production by PBMCs stimulated ex vivo with
C. cassiicola in healthy controls (n = 2 donors, each tested in 3–4 technical replicates) and our patient (n = 2 different blood
draws, tested in 3–4 technical replicates). (C) Shows similar experiments using PBMCs from 2 CARD9-deficient patients (1
blood draw per patient tested in 3–4 technical replicates), compared to 1 healthy donor tested in 4 technical replicates. Data in
panels B and C were analyzed by 2-way ANOVA with Bonferroni’s correction. **P < 0.01, ****P < 0.0001.

Patient CARD9.2 initially developed subcutaneous C. cassiicola phaeohyphomycosis at age 4 in Colombia (21) and was
admitted to the NIH Clinical Center at age 12. She had extensive, uncontrolled disease involving subcutaneous tissues of her
face, adjacent bones, and brain (Figure 1, G–I). As with our index
patient, biopsy of infected lesions demonstrated ineffective
granulomatous inflammation, with fungal elements engulfed
within macrophages (Figure 1J and Supplemental Figure 5).
Over a 13-month hospital admission, the patient developed progressive fatal infection despite treatment with amphotericin B,
posaconazole, micafungin, and terbinafine, repeated surgical
debridements, and allogeneic hematopoietic stem cell transplantation. Thus, our index patient is compound heterozygous
for CLEC7A mutations, which cause functional Dectin-1 deficiency associated with production of a protein with an altered
extracellular C-terminal domain. Mechanistically, our Dectin-1–deficient patient is clinically and histologically similar and
similarly defective in TNF-α production to a CARD9-deficient
patient who developed fatal C. cassiicola phaeohyphomycosis.
Dectin-1 binds and mediates proinflammatory cytokine responses to C. cassiicola. We further investigated the immunological
relevance of Dectin-1 deficiency in our index patient. We asked
whether Dectin-1–sensing pathogen-associated molecular patterns were present on the C. cassiicola surface by staining with

soluble Dectin-1 molecules (29). Indeed, C. cassiicola had Dectin-1
binding sites at filamentous branching points and leading ends,
where conidia are released and bud scars form (Figure 2A).
We next examined the dependence on Dectin-1 for mounting
proinflammatory cytokine responses to this fungus by stimulating PBMCs from the Dectin-1–deficient patient with C. cassiicola.
PBMCs from CARD9-deficient patients and heathy volunteers
served as controls. PBMCs from the Dectin-1–deficient patient
produced significantly less TNF-α and IL-1β in response to C. cassiicola (Figure 2B), similar to CARD9-deficient PBMCs (Figure
2C). By contrast, responses to the Toll-like receptor (TLR) agonists
LPS and Pam3CSK4 were normal, confirming selective impairment of antifungal responses (Supplemental Figure 6). Collectively, these data indicate that Dectin-1 binds and mediates proinflammatory cytokine responses to C. cassiicola.
Dectin-1 and CARD9 deficiencies predispose to subcutaneous
C. cassiicola phaeohyphomycosis in mice. Human CARD9 deficiency underlies progressive subcutaneous C. cassiicola phaeohyphomycosis (4, 21). We modeled subcutaneous C. cassiicola
phaeohyphomycosis in mice to determine whether Dectin-1 is
important for defense against this fungus in a controlled experimental setting. Following subcutaneous fungal inoculation,
wild-type (WT) mice exhibited swollen footpads during the
first week, which resolved over the next 2–3 weeks (Figure 3A).
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Figure 3. Dectin-1 and CARD9 deficiencies heighten infection susceptibility in a murine model of Corynespora cassiicola phaeohyphomycosis. (A) Footpad swelling after infection in WT (week 1 n = 27, week 2 n = 25, week 3 n = 20, week 4 n = 20), Clec7a–/– (week 1 n = 17, week 2 n = 18, week 3 n = 14, week
4 n = 14), and Card9–/– (week 1 n = 10, week 2 n = 10, week 3 n = 11, week 4 n = 10) mice. Data were pooled from 3 independent experiments and analyzed
by 2-way ANOVA with Bonferroni’s correction. (B) Representative images of footpad swelling and histological analysis (on day 10 after infection) used to
generate data shown in panel C, which is the area of footpad occupied by fungal cells on day 10 after infection (WT n = 10, Clec7a–/– n = 9, Card9–/– n = 7).
Data in panel C were pooled from 3 independent experiments and analyzed using Mann-Whitney U test. Scale bars: 500 μm (B, second row) and 50 μm (B,
third row). (D) C. cassiicola burdens in the footpad using qPCR-based quantification in WT (n = 6), Clec7a–/– (n = 8), and Card9–/– (n = 6) mice. Fungal DNA
determined relative to standard curve of purified C. cassiicola genomic DNA (see Methods). Data were analyzed by 1-way ANOVA with Dunnett’s multiple comparison correction. (E) Footpad swelling in monocyte/macrophage-specific CARD9-deficient (Card9fl/fl Cx3cr1CreER+/–, n = 7) mice compared to their
Cre-negative (CARD9-sufficient, n = 11) littermate controls. (F) Footpad swelling in Rag1–/– mice (n = 14) compared to their WT controls (n = 13). (G) Footpad
swelling and fungal burdens in WT (n = 7), Clec7a–/– (n = 7), and Card9–/– (n = 7) mice infected in the hind footpad with 5 × 106 CFU of C. albicans SC5314.
Data in panels E–G were pooled from 2 independent experiments and analyzed by 2-way ANOVA with Bonferroni’s correction. Fungal burden data in panel
G were analyzed by Mann-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.005.

Card9 –/– mice exhibited footpad swelling that was significantly greater than that of WT mice (Figure 3, A and B). We were
unable to quantify live fungal organisms from the infected footpads by culture due to the mycelial growth of the fungus impeding CFU-based quantification. We therefore first used histological analysis, which revealed large granulomas with neutrophils
6

surrounded by lymphocytes and histiocytes and significantly
increased C. cassiicola invasion within granulomas of Card9 –/–
mice. The increased presence of fungal organisms was confirmed by fungal qPCR (Figure 3, B–D). Notably, Clec7a–/– mice
also exhibited significantly greater footpad swelling, C. cassiicola invasion within granulomas, and footpad fungal burden by
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Figure 4. Dectin-1 and CARD9 promote TNF-α and IL-1β production during experimental Corynespora cassiicola phaeohyphomycosis that enhances macrophage C. cassiicola killing. (A) Cytokine analysis in the infected footpad homogenates (WT n = 12 mice, Clec7a–/– n = 12 mice, Card9–/– n = 7 mice) on day 3
after infection. Each data point represents an individual mouse; data were pooled from 2 independent experiments. (B) Footpad swelling in Il1r–/– (day 5: WT
n = 24, KO n = 23, 3 pooled experiments; day 10: WT n = 16, KO n = 20, 4 pooled experiments), Il1b–/– (WT n = 7, KO n = 5, 1 experiment), and Tnfa–/– (day 5: WT n
= 13, KO n = 15, 2 pooled experiments; day 10: WT n = 5, KO n = 15, 2 pooled experiments) mice, relative to WT controls. (C) Total numbers of neutrophils (live
CD45+CD11b+Ly6G+) and macrophages (live CD45+CD11b+MHCIIhiF4/80+) in the infected footpad on day 3 after infection (n = 6 mice per group), measured using
flow cytometry. (D) IL-1β and TNF-α production within footpad macrophages on day 3 after infection in Clec7a–/– (n = 7) and Card9–/– mice (n = 6), normalized to
the WT controls (n = 6). Each data point represents an individual mouse; data were pooled from 2 independent experiments and analyzed by 1-way ANOVA with
Dunnett’s correction. (E) Results of an in vitro C. cassiicola killing assay with bone marrow–derived macrophages, prestimulated for 24 hours with TNF-α, IL-1β,
or both. Killing was determined by measuring β-D-glucan levels in the culture supernatant. Bar graph shows the mean ± SEM for 2 independent experiments;
overlaid dot plot shows technical replicates from one of these experiments. (F) Schematic representation of the proposed model of anti–C. cassiicola immunity
in the footpad of WT, Dectin-1–deficient, and CARD9-deficient mice. Data in panels A and B were analyzed by 2-way ANOVA with Bonferroni’s correction. Data in
panel E were analyzed by unpaired, 2-tailed t test. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001.

qPCR compared with WT mice, albeit to a lesser extent than
Card9 –/– mice (Figure 3, A–D). Therefore, Dectin-1 is necessary
for defense against experimental C. cassiicola infection.
To define which immune cells mediate protective immunity
during subcutaneous C. cassiicola phaeohyphomycosis, we infected monocyte/macrophage-specific CARD9-deficient Card9fl/fl
Cx3cr1CreER mice (15) and found that CARD9 deficiency in monocytes/macrophages enhanced infection susceptibility relative to
WT controls (Figure 3E). By contrast, Rag1–/– mice that lack lym-

phocytes were not susceptible (Figure 3F). Thus, monocyte/macrophage-dependent responses protect, while adaptive immunity is
dispensable in this model.
Next, we examined the fungal specificity of the Dectin-1 and
CARD9 dependence for defense during subcutaneous infection.
Our patient did not manifest mucocutaneous candidiasis and Clec7a–/– mice control oropharyngeal candidiasis normally (30). During
subcutaneous candidiasis, Card9–/– mice were susceptible, showing
increased footpad swelling and fungal burden compared with WT
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Figure 5. Deleterious CLEC7A mutations associated with impaired Dectin-1 responses are frequent among patients with severe phaeohyphomycosis.
(A) Relative frequency of deleterious CLEC7A mutations with high CADD scores (>20) at the population level (calculated using data from 1000 Genomes)
and in the index patient and 17 additional unrelated patients with severe forms of phaeohyphomycosis who were enrolled consecutively over an 8-year
period at the NIH (see Table 1 for details). Data were analyzed by Fisher’s exact test. ****P < 0.0001. (B) Mean fluorescence intensity (MFI) values for
Dectin-1 surface expression in CD14+ monocytes isolated from 8 healthy donors (black dots, see Supplemental Table 1 for details), 5 phaeohyphomycosis
patients without CLEC7A mutations (gray dots), and 6 phaeohyphomycosis patients carrying CLEC7A mutations (green, red, and blue dots as indicated).
FACS staining was performed using an antibody that targets the C-terminus where the CLEC7A mutations reside. No PBMCs were available for testing in
the other patients with severe phaeohyphomycosis, including the one carrying the c.547C>T (p.Leu183Phe) variant (Table 1). FACS histograms show representative Dectin-1 staining for healthy control (black line), a patient homozygous for p.Y238* (red line), and patients heterozygous for p.Y238* (green
line) or p.I223S (blue line) relative to isotype staining control (filled gray histogram). (C) TNF-α production by PBMCs stimulated with particulate β-glucan
for 48 hours, from the same patients as shown in panel B. One blood draw was tested per healthy donor or patient in 3–12 technical replicates and the
mean value per individual is depicted. Data were analyzed by 1-way ANOVA with Dunnett’s correction. *P < 0.05, **P < 0.01. NS, not significant.

mice. By contrast, Clec7a–/– animals controlled subcutaneous candidiasis similarly to WT (Figure 3G). Therefore, mouse Dectin-1 deficiency confers susceptibility to C. cassiicola but not Candida albicans
subcutaneous infection, reflecting the fungus-specific susceptibility
of our Dectin-1–deficient patient to C. cassiicola infection.
Dectin-1– and CARD9-dependent IL-1β and TNF-α contribute
to protection during subcutaneous C. cassiicola phaeohyphomycosis.
We next asked which cytokines protect during C. cassiicola phaeohyphomycosis and their dependence on Dectin-1/CARD9 signaling for production in vivo. We focused on IL-1α, IL-1β, TNF-α,
and IFN-γ, whose production was abrogated in our index patient’s
PBMCs upon C. cassiicola stimulation, and on IL-17A, which was
produced normally by the patient’s PBMCs but promotes mucocutaneous antifungal immunity in other settings (Figure 2B and
Supplemental Figure 7) (31, 32). The levels of IL-1α, IFN-γ, and
IL-17A were not decreased within infected footpad homogenates
of Clec7a–/– and Card9 –/– mice relative to WT mice (Figure 4A).
Although IFN-γ levels were similar, we examined its role further
since recombinant IFN-γ had been administered as part of our
index patient’s successful treatment. We found normal IFN-γ production by CD4+ T cells and intact expression of IFN-γ receptor 1
(IFN-γR1) by myeloid cells in the footpads of Clec7a–/– and Card9 –/–
mice relative to WT mice (Supplemental Figure 8, A and B). Moreover, we found similar fungal burdens in WT and Ifng–/– mouse
footpads (Supplemental Figure 8C), collectively indicating that
IFN-γ is dispensable for control of C. cassiicola infection in this
model. These data are consistent with the lack of reported phaeohyphomycosis in patients with inherited IFN-γR deficiencies,
neutralizing autoantibodies against IFN-γ, or receiving the IFN-γ–
targeting monoclonal antibody emapalumab (23, 33, 34).
8

By contrast, the levels of IL-1β and TNF-α were significantly
decreased within infected footpad homogenates of Clec7a–/– and
Card9 –/– mice compared with WT mice (Figure 4A). To determine
whether decreased IL-1β and TNF-α production during infection
may contribute to the impaired protection seen in Clec7a–/– and
Card9 –/– mice, we infected IL-1 receptor type 1– (IL-1R1–), IL-1β–,
and TNF-α–deficient mice and found them to exhibit increased
footpad swelling after C. cassiicola infection (Figure 4B). Collectively, these data indicate that IL-1β and TNF-α contribute to
protection during experimental C. cassiicola phaeohyphomycosis,
and their production depends on Dectin-1/CARD9 signaling in
mice and humans.
IL-1β and TNF-α enhance macrophage killing of C. cassiicola.
Since macrophages, IL-1β, and TNF-α contribute to anti–C. cassiicola defense, we examined how these cytokines may promote protective macrophage-dependent immunity. Macrophage accumulation did not differ in C. cassiicola–infected subcutaneous tissue
between WT, Clec7a–/–, and Card9 –/– mice (Figure 4C). Similarly,
Dectin-1 and CARD9 were dispensable for neutrophil accumulation in C. cassiicola–infected subcutaneous tissues (Figure 4C).
Thus, CARD9 promotes neutrophil recruitment in a fungus- and
tissue-specific manner, as it mediates neutrophil recruitment in
C. albicans–infected brain and Phialophora-infected subcutaneous tissues (15, 18). Notably, although macrophage accumulation
was unaffected, macrophage production of TNF-α and IL-1β was
significantly decreased in the absence of Dectin-1 or CARD9
in C. cassiicola–infected subcutaneous tissue (Figure 4D). We
hypothesized that TNF-α and IL-1β directly enhance the fungal
killing capacity of macrophages, since these cytokines are known
to enhance macrophage antimicrobial killing pathways (35), and
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we had observed poor containment of fungal growth within macrophages in the soft tissue biopsy of our index patient (Figure 1B
and Supplemental Figure 1). Indeed, stimulation of macrophages
with both IL-1β and TNF-α, but not either cytokine alone, significantly increased C. cassiicola killing compared with unstimulated
cells (Figure 4E). Of note, macrophage killing of C. cassiicola did
not depend on ROS, since blocking the production of ROS did not
impair macrophage killing of the fungus in vitro (Supplemental
Figure 9). Together, our data support a model in which Dectin-1–
mediated C. cassiicola recognition by CARD9-expressing macrophages promotes TNF-α and IL-1β production, which enhances
macrophage nonoxidative fungal killing during experimental C.
cassiicola phaeohyphomycosis (Figure 4F).
Deleterious CLEC7A mutations associated with impaired Dectin-1 responses are frequent in patients with severe phaeohyphomycosis. To examine the potential broader implications of impaired
Dectin-1 responses in human phaeohyphomycosis, we evaluated
17 other unrelated, putatively immunocompetent individuals
with severe forms of phaeohyphomycosis who were enrolled consecutively over an 8-year period at the NIH Clinical Center. We
found CLEC7A mutations with high CADD scores (>20) in 12 of
them (70.9%) (Table 1). Combined with our index patient with
C. cassiicola infection, 13 out of 18 (72.2%) patients with severe
phaeohyphomycosis carried deleterious CLEC7A mutations: 5
with biallelic and 8 with heterozygous CLEC7A mutations. This
represents a significantly greater frequency than that seen at the
population level, evidenced by comparing to healthy individuals
recorded in 1000 Genomes (https://www.internationalgenome.
org/. Accessed January, 2021) (263 out of 2,504, 10.5%; P <
0.0001, Fisher’s exact test) (Figure 5A). Moreover, we found significantly reduced binding of the C-terminus–targeted anti–Dectin-1 antibody on the surface of monocytes and decreased TNF-α
production upon β-glucan stimulation by PBMCs of patients with
phaeohyphomycosis carrying CLEC7A mutations, consistent with
impaired Dectin-1–dependent responses in these patients (Figure
5, B and C). Impaired TNF-α production was observed across Dectin-1 p.Y238* homozygous (red symbols) and heterozygous (green
symbols) and Dectin-1 p.I223S heterozygous (blue symbols)
patient PBMCs (Figure 5C), similar to the previously reported
decreased proinflammatory cytokine production in heterozygous
and homozygous Dectin-1 p.Y238* PBMCs (19, 20, 36–38), suggesting that p.Y238* and p.I223S may act in a dominant-negative
manner. Collectively, these data indicate that impaired Dectin-1
responses may have contributed to severe phaeohyphomycosis in
more than 50% of patients in our cohort with this infection.

Discussion

We report a patient with Dectin-1 deficiency with severe C. cassiicola phaeohyphomycosis, an infection previously reported
in inherited CARD9 deficiency. Therefore, Dectin-1 deficiency
may phenocopy CARD9 deficiency with respect to susceptibility to this dematiaceous fungus in the setting of traumatic fungal
inoculation. We show that Dectin-1 binds to C. cassiicola and promotes proinflammatory cytokine production by human PBMCs.
In C. cassiicola–infected mice, Dectin-1 and CARD9 deficiencies
impaired fungal control and decreased production of TNF-α and
IL-1β, which contribute to protective immunity via macrophage

fungal killing. Moreover, in an additional 12 out of 17 unrelated
patients with severe forms of phaeohyphomycosis, we identified
heterozygous or biallelic deleterious CLEC7A mutations associated with an altered Dectin-1 extracellular β-glucan–binding
domain, impairing TNF-α production in response to fungal stimulation. Collectively, these data underscore the importance of Dectin-1 in antifungal immunity to phaeohyphomycetes.
C. cassiicola causes multiple diseases in plants (39). It also
rarely causes human phaeohyphomycosis, affecting diabetic
(40), CARD9-deficient (4, 21, 41), and apparently immunocompetent patients (42–44). Human Dectin-1 deficiency caused by
p.Y238* homozygosity was previously associated with vulvovaginal candidiasis and onychomycosis (19). This susceptibility was
linked to impaired Dectin-1–mediated recognition of Candida and
decreased production of IL-17A and TNF-α (19). The p.Y238* mutation has also been associated with increased risk of mucosal Candida colonization and invasive aspergillosis in the setting of allogeneic hematopoietic stem cell transplantation, linked to impaired
production of proinflammatory cytokines by PBMCs of heterozygous and homozygous patients (20, 38). We show here that whereas p.Y238* Dectin-1 protein is produced at adequate levels, it has an
altered extracellular, β-glucan–binding, C-terminal domain, which
could affect the innate recognition of C. cassiicola. We found that
the C-terminal domain of Dectin-1 bound C. cassiicola at branching buds and hyphal tips, representing one of the first insights to
our knowledge into innate recognition of this specific fungus.
Whether other CARD9-coupled CLRs, TLRs, or other pattern recognition receptors can engage ligands within the C. cassiicola cell
wall and initiate protective immunity, either alone or collaboratively, remains to be determined. Based on our data, we propose
that human Dectin-1 deficiency contributes to severe C. cassiicola
phaeohyphomycosis, and that deleterious CLEC7A (and CARD9)
mutations should be sought in affected patients.
The rarity of C. cassiicola phaeohyphomycosis is notable relative
to the frequency of human Dectin-1 deficiency, as approximately 5
and approximately 0.1 out of 1,000 individuals are homozygous
for p.Y238* and p.I223S, respectively. Therefore, these deleterious
CLEC7A variants in themselves do not represent a primary immunodeficiency per se. By contrast, these population CLEC7A variants
are relatively benign unless the carrier is traumatically exposed to
C. cassiicola or certain other phaeohyphomycetes to instigate disease, after which impaired Dectin-1–dependent immune responses
appear to contribute to suboptimal infection control. The contribution of common population variants to infection susceptibility has
been previously shown. For example, common heterozygous CFTR
mutations are associated with increased risk of respiratory infections (45, 46). Furthermore, the common homozygous CCR5Δ32
mutation (~1% of Whites) increases the risk of severe West Nile
virus infection upon exposure to the virus by mosquitos (47–49).
Moreover, the common homozygous TYK2 P1104A mutation (~1
out of 600 of Europeans) increases the risk of tuberculosis upon
exposure to Mycobacterium tuberculosis (50). Indeed, most cases of
human C. cassiicola infections are reported to develop in the setting of physical injuries, as with our index patient (42). In addition,
the low virulence of C. cassiicola associated with its marked growth
restriction at temperatures greater than 30°C (39) and its preferential habitat on crop plants and debris (51) further limits the avail-
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able opportunities for this fungus to cause human infection, and
thus may additionally explain the rarity of this infection despite
the relatively high frequency of deleterious CLEC7A variants in the
general population. Of note, these deleterious CLEC7A mutations
are enriched in the San population of South Africa, a region where
subcutaneous mycoses are common (19, 52). Whether genetic variation in the CLR/CARD9 pathway may explain, at least partly, the
increased prevalence of subcutaneous mycoses in certain subtropical regions warrants investigation. Our findings, together with
the accompanying report by Hsu and colleagues (53), imply that
Dectin-1 may be critical to the optimal development of antifungal
defense following traumatic inoculation by low-virulence, dematiaceous fungi (Corynespora), or inhalational exposure to highly virulent fungi in certain geographic areas (Coccidioides).
To study the immunopathogenesis of C. cassiicola phaeohyphomycosis, we modeled it in mice. We used footpad swelling
as a surrogate measure of infection control, which we found correlated to tissue fungal burden, although differential swelling in
different gene-deficient mice may also be due to inappropriate
inflammation and inability to form or resolve granulomas. Using
this model, we found that Dectin-1 and CARD9 were each required
for anti–C. cassiicola defense, which depended on macrophages,
and TNF-α and IL-1β were critical for protection and macrophage
fungal killing. The mechanism by which macrophages mediate C.
cassiicola killing remains to be determined, although our data indicated that ROS was either not involved or could be compensated
by additional nonoxidative mechanisms. These data are consistent
with the normal oxidative burst of our index patient and the lack
of reported phaeohyphomycosis in patients with chronic granulomatous disease who lack phagocyte oxidative burst (34, 54).
Moreover, future studies will be required to determine whether
human monocyte-derived macrophages also rely on TNF-α and
IL-1β in an interdependent manner for anti–C. cassiicola defense.
By contrast, neutrophil accumulation was unaffected by Dectin-1
and CARD9 deficiency in this model, although we cannot rule out
functional deficits in these cells or that reduced IL-1β and TNF-α
may have had an effect on fungal uptake and killing by neutrophils;
these questions will require further study using neutrophil-specific Dectin-1– and CARD9-deficient mice. However, we found
that monocyte/macrophage-specific CARD9-deficient mice had
enhanced susceptibility to C. cassiicola infection, indicating that
macrophage defects are the primary driver of the disease in this
model. In addition to intact neutrophil recruitment, we also found
that IL-17A production within C. cassiicola–infected footpads were
Dectin-1 and CARD9 independent. This contrasts with Phialophora
and Exophiala phaeohyphomycoses, where neutrophil recruitment
and IL-17A production were shown to be CARD9 dependent (3,
18). Thus, CLR/CARD9-dependent protection against phaeohyphomycosis may utilize differential fungal species–specific mechanisms, which merit further investigation. Future studies should
decipher potential additional Dectin-1– and CARD9-dependent
anti–C. cassiicola protective cellular and molecular mechanisms
and define which Dectin-1–independent CARD9-dependent CLRs
may also participate in defense against C. cassiicola and other
dematiaceous fungi in mice and humans. Of note, a recent report
indicated that impaired Dectin-2–dependent immune responses
may have contributed to the development of fatal invasive asper10

gillosis in an immunosuppressed patient (55). Additional studies
will be required to examine the mechanisms by which p.Y238*
and p.I223S may act in a dominant or co-dominant manner and
to model and study phaeohyphomycosis caused by Cladophialophora, Bipolaris, Curvularia, and other melanin-bearing agents of
phaeohyphomycosis in WT, Dectin-1–deficient, CARD9-deficient,
and heterozygous and homozygous p.Y238* and p.I223S mice.
Moreover, the identification of deleterious CLEC7A mutations in
approximately 70% of patients with severe phaeohyphomycosis in
our cohort requires validation in future studies with more patients
manifesting various fungus- and tissue-specific forms of severe
phaeohyphomycosis. Furthermore, the role of prolonged antifungal therapy and/or long-term secondary antifungal prophylaxis in
patients with severe phaeohyphomycosis who carry deleterious
CLEC7A mutations requires further study.
In summary, we show that Dectin-1 deficiency may contribute
to susceptibility to severe phaeohyphomycosis by certain dematiaceous fungi upon traumatic inoculation. Our findings provide
mechanistic insights into the pathogenesis of phaeohyphomycosis
and may help improve the diagnosis and management of immunocompetent patients who develop this infection.

Methods

Whole-exome sequencing. Sequencing libraries were generated using
the TruSeq DNA Sample Prep Kit (Illumina), following the NimbleGen
SeqCap EZ Library SR User’s Guide, v4.0 (Roche Nimblegen, Inc.).
Briefly, 1 μg of each gDNA was sheared using the Covaris instrument
and Covaris microTUBEs (Covaris, Inc.). The following shearing conditions were used: duty cycle, 10%; intensity, 5.0; bursts per second,
200; duration, 120 seconds; mode, frequency sweeping; temperature,
5.5°C to 6.0°C. Each sample was prepared with a specific indexing
adapter to facilitate multiplex pooling in the exon enrichment procedure. Exome enrichment was performed using the SeqCap EZ Human
v3.0 Exome Enrichment kit on 200 ng of each TruSeq library. Libraries
were combined to create a 6-plex reaction for the enrichment, yielding
a total DNA library mass of 1,200 ng. One microgram of the 6-plex
pooled libraries was hybridized to capture target oligonucleotides for
48 hours, as specified in the manufacturer’s protocol.
Exome-enriched libraries were quantified using the KAPA Library
Quantification Kit (KAPA Biosystems), clustered on the cBot Cluster
Station, and sequenced as 2 × 100 bp reads on the HiSeq 2500 instrument, according to the manufacturer’s protocol (Illumina).
High-quality, trimmed paired-end sequence reads were mapped
to the human genome reference consortium GRGh37 (hg19) using
Bowtie 2 and the default parameters with mixed mode disabled (57).
Multiply mapped reads and PCR duplicates were removed using SAMtools (sequence alignment/map) (57). Additional filtering of the prealigned BAM files to remove reads with low-quality base, mapping,
and alignment scores was performed prior to variant detection using
Strand NGS 2.1 software (Strand Genomics, Inc.) and the following
parameters: mapping quality threshold 20 or greater, base quality 17
or greater, and alignment score 85 or greater. Aligned reads were also
base quality score recalibrated and locally realigned around indels.
Reads were filtered against the SeqCap EZ Exome v3.0 target region
(64 Mb exonic sequences) and reads greater than 100 bp outside of
the targeted region were excluded from further analyses. The average
coverage depth was 75× from approximately 1.9 Gb. Identification of
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SNPs and indels was performed using Strand NGS software. Strand
NGS utilizes a modified Bayesian variant calling method adapted
from the MAQ SNP calling algorithm which compares the nucleotides
present on aligned reads against the reference at each position in the
genome. The dbGaP study accession numbers are phs001899.v2.p1
and phs001561.
CLEC7A sequencing. Genomic DNA was isolated from peripheral
blood leukocytes using a Gentra Puregene DNA isolation kit (Qiagen)
and amplified using Platinum Taq PCR SuperMix High Fidelity (Thermo Fisher Scientific) following the manufacturers’ protocols with
primers and cycling conditions listed in Supplemental Table 2. PCR
products were purified with Exo-SAP IT (Thermo Fisher Scientific)
and sequenced using BigDye Terminators v3.1 (Applied Biosystems)
per the manufacturers’ instructions using primers listed in Supplemental Table 3. Reactions were purified over Performa DTR plates (Edge
Biosystems) and resulting products run on an ABI 3730XL capillary
sequencer. Chromatograms were analyzed using Sequencher (GeneCodes) and compared to the NCBI reference sequence, NM_197947.
C. cassiicola culture. The C. cassiicola strain used in all experiments
was isolated from our Dectin-1–deficient patient. C. cassiicola was stored
in 50% glycerol at –80°C, and routinely grown on potato dextrose agar
(PDA; Sigma-Aldrich) plates at 20°C for 7 days, harvested, and replated onto fresh PDA plates and grown for an additional 7 days before use.
To harvest C. cassiicola, 10 mL sterile tissue-culture grade water (Gibco) was added to each plate, and a soft paint brush (sterilized in 70%
ethanol and rinsed in sterile water) used to brush the colonies and lift
fungal cells. The fungi and water were pipetted off the plate, and a further wash/brush repeated with 5 mL of water. The resulting suspension
was centrifuged (1,800g for 4 minutes) to pellet C. cassiicola, which was
resuspended in sterile PBS. Each suspension was adjusted to an OD600
of 2.0 for use in experiments. Microscopy analysis and analysis of Dectin-1 ligand exposure was performed as outlined below.
Dectin-1 ligand staining. C. cassiicola was prepared as above and 50
μL used for staining. Pelleted fungal cells were resuspended in 1 mL
2% paraformaldehyde and incubated at room temperature for 10 minutes. Fungi were centrifuged again and supernatants discarded, before
washing in 1 mL PBS. Cell pellets were resuspended in 400 μL 10%
mouse serum/PBS and incubated for 15 minutes at room temperature
to block, and then washed in 1 mL PBS. Cells were resuspended in 100
μL PBS and 1 μL Fc-Dectin-1 (29) added to the cells, incubating at 4°C
for 1 hour with continual slow rotation. Fungi were washed twice in
PBS, and then stained with 2 μg/mL anti–human IgG–PE secondary
in 100 μL PBS for 30 minutes at 4°C. Cells were washed twice in PBS,
resuspended in 20 μL PBS, added to microscope slides, and analyzed
with a Leica fluorescence microscope equipped with ZEN software. C.
albicans germ tubes (induced in 20% FBS/water for 1 hour at 37°C)
were used as a positive control, and secondary-only–stained samples
used as a negative control.
Preparation of PBMCs. PBMCs from the Dectin-1–deficient
patients, CARD9-deficient patients, or healthy donors, were harvested from whole blood by gradient centrifugation using Lymphocyte Separation Media (Lonza), according to the manufacturer’s
instructions. PBMCs were washed in PBS and resuspended in 10%
DMSO/FBS, and slowly frozen before storing in liquid nitrogen. Frozen PBMCs were defrosted in a 37°C water bath and washed in RPMI
1640 supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/
mL streptomycin (hereafter referred to as “complete RPMI”) prior to

counting with trypan blue exclusion. Washed PBMCs were used for
stimulation assays or flow cytometry.
PBMC stimulation assay. PBMCs (5 × 105) were incubated in a
round-bottom 96-well plate (Corning) at 37°C in a 5% CO2 incubator
in complete RPMI, supplemented with either 200 ng/mL LPS (Sigma-Aldrich), 1 μg/mL Pam3CSK4 (Sigma-Aldrich), α-mannan (see
below), β-glucan (see below), or heat-killed (incubation at 70°C for 1
hour) C. cassiicola, which was added at a 1:12 dilution to the cells. After
48 hours, PBMCs were pelleted and the supernatant was collected and
stored at –80°C until analysis. Cytokine levels were analyzed via conventional ELISA (Figure 5B; TNF-α DuoSet, R&D Systems, DY210) or
Luminex (Figure 1F). Luminex analysis was done via a multiplex bead
array assay with antibodies and cytokine standards (R&D Systems,
Peprotech). Individual Luminex bead sets (Luminex) were coupled to
cytokine-specific capture antibodies according to the manufacturer’s
protocols and biotinylated polyclonal antibodies were used at twice
the recommended concentrations for a classical ELISA according to
the manufacturer’s instructions. The assay was run with 1,200 beads
per set of cytokines in a volume of 50 μL. The plates were read on a
Luminex MAGPIX platform where more than 50 beads were collected
per bead set. The median fluorescence intensity of the beads was then
measured for each individual bead, which was analyzed with the Millipex software using a 5P regression algorithm.
β-Glucan and α-mannan preparations. Carbohydrates were purified as described previously (see main text for references), and then
prepared for PBMC stimulation. In brief, 5 mg of particulate β-glucan
was added to 1 mL water, sonicated for 30 seconds, pelleted by centrifugation at 10,000g for 10 minutes and resuspended in complete RPMI
for use in stimulation experiments at the indicated concentrations. For
α-mannan, 5 mg was dissolved in PBS, mixed at room temperature
for 2 hours with shaking, centrifuged at 10,000g for 10 minutes, and
resuspended in complete RPMI at indicated concentrations for stimulation experiments.
Dectin-1 expression by flow cytometry. PBMCs were isolated as
above, resuspended in PBS, and Fc receptors blocked with antiCD16/32 (BD Biosciences) on ice for 10 minutes prior to staining with
anti–human CD14–FITC (Biolegend, clone HCD14) and anti–human
Dectin-1–PE (Biolegend, clone 15E2), or the appropriate isotype
control (Biolegend, IgG2a clone MOPC-173), on ice for 30 minutes.
Stained samples were washed in PBS and acquired using a BD LSR,
equipped with BD FACSDiva software. FlowJo (BD) was used for the
final analysis.
Dectin-1 immunoblot analysis. Whole-cell lysates were suspended in 1× RIPA buffer containing protease and phosphatase inhibitors
(Thermo Fisher Scientific). The lysates were centrifuged at approximately 14,000g for 15 minutes at 4°C. Supernatants were collected
and protein concentrations were determined using the Bradford Protein Assay (Bio-Rad), according to the manufacturer’s protocol. The
proteins (20 μg) were resolved in 12% SDS-PAGE and electrotransferred onto 0.2 μm PVDF. Membranes were blocked in 5% BSA and
incubated with primary antibody against Dectin-1 (Invitrogen, PA534382) and β-actin (Cell Signaling Technology, clone D6A8), followed
by secondary anti–rabbit IgG, HRP-linked antibodies (Cell Signaling
Technology). Chemiluminescence detection was performed with
Clarity Western ECL Blotting Substrate (Bio-Rad), using the ChemiDoc MP Imaging System (Bio-Rad). Quantification was obtained by
densitometry image analysis using Image Lab 5.2 software (Bio-Rad).
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HEK293 transfection. WT Dectin-1 expression plasmid (Origene,
clone SC307610, NM_197947) was used for site-directed mutagenesis to generate the patient variant, c.714T>G; p.Y238*. HEK293
cells (ATCC) were plated at 5 × 105 cells/well in a 6-well plate and
allowed to rest overnight. The following day, cells were transfected
using 2 μg WT or p.Y238* plasmid and Fugene HD reagent (Promega) at a 3:1 ratio. Twenty-four hours later, cells were harvested for
immunoblot analysis.
Mice. Eight- to 12-week-old female mice were maintained in individually ventilated cages under specific pathogen–free conditions
at the NIH. The following strains (and their respective WT controls/
littermates) were obtained from the NIAID Taconic contract; Rag1–/–,
Il1r1–/–, Tnfa–/–, and Ifng–/–. All other strains and their respective controls/littermates were bred in-house at the NIH (Card9 –/–, Clec7a–/–,
Il1b–/–, Card9fl/fl Cx3cr1Cre-ER+/–). In experiments using Cre-expressing
mouse lines, mice were pretreated with 3 mg tamoxifen (dissolved in
Miglyol 812, The Warner Graham Company) daily by intraperitoneal
injection for 5 days prior to infection. Animals were infected and analyses performed as outlined below. Animals were euthanized by cervical dislocation following administration of ketamine/xylazine cocktail
at defined time points after infection (see figure legends).
Footpad infections. C. cassiicola was prepared as above and 50 μL
injected into the left hind footpad of each mouse using a 21-G needle. Footpad swelling was measured once per week using calipers,
measuring the height of the foot just below the toes at the widest part
of the foot. The right uninfected footpad was measured and swelling expressed as a percentage relative to the uninfected footpad for
each individual mouse. For C. albicans footpad infections, C. albicans
SC5314 was grown in YPD broth overnight at 30°C with shaking at 200
rpm, washed in PBS, and counted with a hemocytometer. Yeast cells (5
× 106) were injected into the left hind footpad in a 50 μL volume and
footpad swelling measured every 2 days as described above. C. albicans footpad burdens were measured by removing the infected footpad with a scalpel, homogenizing in 0.5 mL sterile PBS, and plating on
YPD agar plates. Viable colonies were counted after incubation at 37°C
for 24 hours and expressed as CFU per gram of footpad tissue.
Footpad flow cytometry and intracellular cytokine staining. Footpads
were removed with a scalpel, finely minced, and digested for 30 minutes at 37°C in digestion medium (RPMI supplemented with 250 μg/
mL Liberase TL and 50 μg/mL DNase [both from Roche]), which was
supplemented with 10 μg/mL brefeldin A (Sigma-Aldrich) for intracellular cytokine staining experiments involving detection of IL-1β and
TNF-α. The resulting cellular suspension was filtered and washed in
PBS. Cells were stained with fluorophore-labeled antibodies against
the following proteins: CD45 (Biolegend, clone 30-F11), Ly6G (Biolegend, clone 1A8), CD11b (Biolegend, clone M1/70), CD11c (eBioscience, clone N418), Ly6C (BD Biosciences, clone AL-21), MHCII
(eBioscience, clone M5/114.15.2), F4/80 (Biolegend, clone BM8),
CD3 (Biolegend, clone 145-2C11), TCRβ (Bioegend, clone H57-597),
CD90.2 (eBioscience, clone 30-H12), CD4 (Biolegend, clone RM4-5),
CD8 (Biolegend, clone 53-6.7), CD19 (Biolegend, clone 1D3), NKp46
(Biolegend, clone 29A1.4), and IFN-γR1 (eBioscience, clone 2E2), and
data were acquired on a BD LSR Fortessa equipped with BD FACSDiva
software. FlowJo (Tree Star) was used for the final analysis. For intracellular cytokine staining of IL-1β and TNF-α, mice were first injected
with 250 μg brefeldin A 6 hours prior to sacrifice. To stain for IFN-γ+
cells, the cells were stimulated with PMA (50 ng/mL) and ionomycin
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(2.5 μg/mL) for 3.5 hours at 37°C and 5% CO2 in a humidified chamber, in the presence of 1 mg/mL brefeldin A. Cells were then fixed/permeabilized using the Foxp3 Staining Buffer Set (eBioscience) prior to
labeling with anti–IL-1β (Invitrogen, clone NJTEN3), anti–TNF-α (Biolegend, clone MP6-XT22), or anti–IFN-γ (eBioscience, clone XMG1.2).
C. cassiicola killing assay. Bone marrow cells from the femurs/
tibias of C57BL/6 females were flushed out with sterile 2 mM EDTA/
PBS, washed, and resuspended in RPMI (with GlutaMAX; Invitrogen)
with 20% FBS (Sigma-Aldrich), 1% penicillin/streptomycin (Invitrogen), and 40 ng/mL M-CSF (Biolegend). Bone marrow cells were
incubated in 75 cm2 tissue culture flasks (Corning) for 5 days, replacing
the media on day 3. On day 5, the media were replaced with ice-cold
2 mM EDTA/PBS and flasks incubated on ice for 10 minutes. Adherent cells (macrophages) were gently lifted using a cell scraper (Gibco)
and counted using trypan blue exclusion. Macrophages were then
seeded into flat-bottom 96-well plates (4 × 105 per well) in RPMI supplemented with 10% FBS and 1% penicillin/streptomycin. Some wells
were additionally supplemented with 10 ng/mL recombinant murine
TNF-α (Biolegend) and/or 10 ng/mL recombinant murine IL-1β (Biolegend), or 5 mM N-acetyl cysteine (Sigma-Aldrich). Macrophages
were incubated overnight at 37°C and 5% CO2. The following day, C.
cassiicola (prepared as above to OD600 = 2.0) was added to the macrophages (50 μL fungal suspension added per well to a final volume of
200 μL) and the incubation at 37°C continued for a further 3 hours.
Culture supernatants were then collected and frozen at –20°C. Concentrations of β-D-glucan in the supernatants were measured using
the Glucatell (1→3)-β-D-glucan detection reagent kit (Cape Cod Associates), as per the manufacturer’s instructions.
Footpad histology and cytokine determination. The infected left
hind foot of WT, Card9 –/–, and Clec7a–/– mice was removed and fixed
in 10% formalin for 24 hours before embedding in paraffin wax. Tissue sections were stained with periodic acid–Schiff (PAS). To estimate
C. cassiicola burden in the footpad, pictures were taken of the entire
footpad section (at least 2 per mouse) and the total area covered by
fungal cells measured using ImageJ software (NIH). For cytokine
analysis, infected footpads were removed with a scalpel and added to 0.5 mL PBS supplemented with 0.05% Tween 20 and a protease inhibitor cocktail (Roche). Footpads were homogenized and cell
debris removed by centrifugation at 1,100g for 5 minutes at 4°C. The
resulting supernatant was snap-frozen on dry ice and stored at –80°C
until analysis. Samples were analyzed by Luminex array as described
above, and cytokine concentrations were determined per milligram of
footpad tissue.
Determination of fungal burden in infected mouse footpads with
qPCR. On day 10 after infection, infected footpads of WT, Card9 –/–,
Clec7a–/–, and Ifng–/– mice were harvested and homogenized in 1 mL
PBS using Omni tip homogenizers (Omni International). To isolate
and quantify DNA from pure C. cassiicola, the fungus was grown as
described above and the fungal suspension was adjusted to an OD600
of 2.0 in 1 mL PBS. The footpad homogenates and pure fungal suspensions were centrifuged at 5,000g, supernatants were discarded,
and the pellets were utilized to isolate DNA as described previously
(58). For qPCR, 20 ng of total DNA, PerfecTa Fast mix (Quanta Biosciences), fungus-specific Fungi-Quant probe/primers targeting the
fungal 18s rRNA gene, and specific cycling program were utilized as
described previously (59). Fungal DNA amount per footpad was interpolated from a series of serially diluted DNA from pure C. cassiicola.
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Statistics. Statistical analyses were performed using GraphPad
Prism 9.0 software. Details of individual tests are included in the figure legends. In general, data were tested for normal distribution by
the Kolmogorov-Smirnov normality test and analyzed accordingly by
unpaired t tests or Mann-Whitney U test. In cases where multiple data
sets were analyzed, either 2-way ANOVA was used with Bonferroni’s
correction (animal experiments) or 1-way ANOVA with Dunnett’s multiple corrections (comparison of healthy controls and patients with/
without Dectin-1 mutations for TNF-α production). See figure legends
for details of tests used for each figure panel. To compare the frequency of deleterious CLEC7A mutations with high CADD scores (>20) in
patients with severe phaeohyphomycosis relative to healthy individuals
recorded in 1000 Genomes, Fisher’s exact was used. In all cases, P values of less than 0.05 were considered significant.
Study approval. Animal studies were performed in accordance with
the recommendations in the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011), under the auspices of
protocol LCIM14E approved by the Animal Care and Use Committee of
the NIAID. The patients and healthy donors were enrolled in protocols
approved by the NIH Institutional Board Review and provided written
informed consent for participation in the study. Patients or their parents provided written consent for their photographs to be published as
part of this study and the record for the consent has been retained. This
study was conducted in accordance with the Declaration of Helsinki.
The Dectin-1–deficient index patient was enrolled in ClinicalTrials.gov
study number NCT00001355. The CARD9-deficient patients and the
additional putatively immunocompetent patients with severe forms of
phaeohyphomycosis (Table 1) were enrolled in ClinicalTrials.gov study
number NCT01386437. The 16 additional patients with severe forms of
phaeohyphomycosis had not received iatrogenic immunosuppression
(e.g., corticosteroids), were HIV negative, and had no prior history of fungal infections or other nonfungal infection susceptibility.

Author contributions

RAD, JVD, APH, VO, JAA, SLA, MS, SV, DY, AK, NSPV, SP, AMZ,
DBK, and MSL performed experiments and analyzed the data.
1. Revankar SG, et al. A mycoses study group international prospective study of phaeohyphomycosis: an analysis of 99 proven/probable cases.
Open Forum Infect Dis. 2017;4(4):ofx200.
2. Revankar SG, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin
Infect Dis. 2002;34(4):467–476.
3. Wang X, et al. Impaired specific antifungal immunity in CARD9-deficient patients with phaeohyphomycosis. J Invest Dermatol. 2018;138(3):607–617.
4. Yan XX, et al. CARD9 mutation linked to Corynespora cassiicola infection in a Chinese patient.
Brit J Dermatol. 2015;174(1):176–179.
5. Lanternier F, et al. Inherited CARD9 deficiency
in 2 unrelated patients with invasive Exophiala
infection. J Infect Dis. 2015;211(8):1241–1250.
6. Drummond RA, Lionakis MS. Mechanistic
insights into the role of C-type lectin receptor/
CARD9 signaling in human antifungal immunity.
Front Cell Infect Microbiol. 2016;6:39.
7. Glocker EO, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361(18):1727–1735.

RAD, JVD, APH, DCV, KDMB, AMZ, CMM, KJKC, JKL, DBK,
SMH, and MSL designed experiments. MSA, MAW, DB, BD, KH,
CSZ, EMNF, MMS, JAB, YRS, CAA, CA, MM, ZT, AGT, M Natarajan, M Nigo, VM, KCB, SGK, MSW, GR, CJW, NM, JGB, LCK,
WRM, AG, AGJ, MS, AFF, JEB, SMH, KB, RH, and MSL provided
clinical care and referred patients. AJO analyzed the genomic data.
TD provided regulatory support to patient enrollment and consenting. KDMB, YI, KJKC, YB, and GDB provided key reagents and
expertise. MSL conceived and supervised the project. RAD and
MSL wrote the final manuscript.

Acknowledgments

This research was supported by the Division of Intramural
Research of the NIAID, the NCI, the NIDCD, and the NIH Clinical Center and in part with federal funds from the NCI, under
contract no. HHSN261200800001E. CAA is supported by NIH/
NIAID grants K24AI121296, R01AI134637, R01AI148342-01,
R21AI143229, and P01AI152999. The content of this publication
does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade
names, commercial products, or organizations imply endorsement by the US Government.
Address correspondence to: Michail S. Lionakis, 9000 Rockville
Pike, Bldg 10, Rm 12C103A, Bethesda, Maryland 20892, USA.
Phone: 301.443.5089; Email: lionakism@mail.nih.gov.
RAD’s present address is: Institute of Immunology & Immunotherapy, Institute of Microbiology & Infection, University of Birmingham, Birmingham, United Kingdom.
JVD’s present address is: Center for Discovery & Innovation,
Hackensack Meridian Health, Nutley, New Jersey, USA.
SV’s present address is: The Binding Site, Birmingham, United
Kingdom.

8. Lanternier F, et al. Inherited CARD9 deficiency
in otherwise healthy children and adults with
Candida species-induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol.
2015;135(6):1558–1568.
9. Gavino C, et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy.
Clin Infect Dis. 2014;59(1):81–84.
10. Corvilain E, et al. Inherited CARD9 deficiency:
invasive disease caused by ascomycete fungi in
previously healthy children and adults. J Clin
Immunol. 2018;38(6):656–693.
11. Lanternier F, et al. Deep dermatophytosis and
inherited CARD9 deficiency. N Engl J Med.
2013;369(18):1704–1714.
12. Drummond RA, et al. Human CARD9: a critical
molecule of fungal immune surveillance.
Front Immunol. 2018;9:1836.
13. Rieber N, et al. Extrapulmonary Aspergillus
infection in patients with CARD9 deficiency.
JCI Insight. 2016;1(17):e89890.
14. Brown GD, et al. C-type lectins in immunity and

homeostasis. Nat Rev Immunol. 2018;18(6):374–389.
15. Drummond RA, et al. CARD9+ microglia promote antifungal immunity via IL-1β- and CXCL1-
mediated neutrophil recruitment. Nat Immunol.
2019;20(5):559–570.
16. Drummond RA, et al. CARD9-dependent neutrophil recruitment protects against fungal invasion
of the central nervous system. PLoS Pathog.
2015;11(12):e1005293.
17. Drewniak A, et al. Invasive fungal infection and
impaired neutrophil killing in human CARD9
deficiency. Blood. 2013;121(13):2385–2392.
18. Wu W, et al. Impairment of immune response
against dematiaceous fungi in Card9 knockout
mice. Mycopathologia. 2016;181(9–10):631–642.
19. Ferwerda B, et al. Human dectin-1 deficiency and
mucocutaneous fungal infections. N Engl J Med.
2009;361(18):1760–1767.
20. Cunha C, et al. Dectin-1 Y238X polymorphism
associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through
impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood.

J Clin Invest. 2022;132(22):e159348 https://doi.org/10.1172/JCI159348

13

RESEARCH ARTICLE

The Journal of Clinical Investigation  

2010;116(24):5394–5402.
21. Arango-Franco CA, et al. Early-onset invasive
infection due to Corynespora cassiicola associated with compound heterozygous CARD9
mutations in a colombian patient. J Clin Immunol.
2018;38(7):794–803.
22. Noel SB, et al. Primary cutaneous phaeohyphomycosis. Report of three cases. J Am Acad Dermatol. 1988;18(5, part 1):1023–1030.
23. Lionakis MS, Levitz SM. Host control of fungal
infections: lessons from basic studies and human
cohorts. Annu Rev Immunol. 2018;36:157–191.
24. Plantinga TS, et al. Functional consequences
of DECTIN-1 early stop codon polymorphism
Y238X in rheumatoid arthritis. Arthritis Res Ther.
2010;12(1):R26.
25. Chai LYA, et al. The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1
and susceptibility to invasive aspergillosis.
J Infect Dis. 2011;203(5):736–743.
26. Ohno N, et al. Solubilization of yeast cell-wall
beta-(1→3)-D-glucan by sodium hypochlorite
oxidation and dimethyl sulfoxide extraction.
Carbohydr Res. 1999;316(1–4):161–172.
27. Uchiyama M, et al. Chemical and immunochemical characterization of limulus factor G-activating substance of Candida spp. FEMS Immunol
Med Microbiol. 1999;24(4):411–420.
28. Mazzurco JD, et al. Phaeohyphomycosis caused by
Phaeoacremonium species in a patient taking infliximab. J Am Acad Dermatol. 2012;66(2):333–335.
29. Graham LM, et al. Soluble Dectin-1 as a tool
to detect beta-glucans. J Immunol Methods.
2006;314(1):164–169.
30. Verma AH, et al. Oral epithelial cells orchestrate
innate type 17 responses to Candida albicans
through the virulence factor candidalysin.
Sci Immunol. 2017;2(17):eaam8834.
31. Puel A, et al. Chronic mucocutaneous candidiasis
in humans with inborn errors of interleukin-17
immunity. Science. 2011;332(6025):65–68.
32. Puel A, et al. Inborn errors of human IL-17
immunity underlie chronic mucocutaneous
candidiasis. Curr Opin Allergy Clin Immunol.
2012;12(6):616–622.
33. Browne SK, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med.
2012;367(8):725–734.
34. Lionakis MS, et al. Mendelian genetics of human
susceptibility to fungal infection. Cold Spring
Harb Perspect Med. 2014;4(6):a019638.
35. Brown GD. Innate antifungal immunity: the

14

key role of phagocytes. Ann Review Immunol.
2010;29:1–21.
36. Brown J, et al. Structure of the fungal beta-glucanbinding immune receptor dectin-1: implications for
function. Protein Sci. 2007;16(6):1042–1052.
37. Dulal HP, et al. β-Glucan-induced cooperative
oligomerization of Dectin-1 C-type lectin-like
domain. Glycobiology. 2018;28(8):612–623.
38. Plantinga T, et al. Early stop polymorphism in
human DECTIN1 is associated with increased
Candida colonization in hematopoietic stem
cell transplant recipients. Clin Infect Dis.
2009;49(5):724–732.
39. Fernando THPS, et al. Some factors affecting in
vitro production, germination and viability of
conidia of Corynespora cassiicola from Hevea
brasiliensis. J Natl Sci Found. 2012;40(3):241–249.
40. Huang H-K, et al. Subcutaneous infection caused
by Corynespora cassiicola, a plant pathogen.
J Infect. 2010;60(2):188–190.
41. Wang WY, et al. Pulmonary Cladosporium infection coexisting with subcutaneous Corynespora
cassiicola infection in a patient: A case report.
World J Clin Cases. 2022;10(11):3490–3495.
42. Lv GX, et al. Phaeohyphomycosis caused by a
plant pathogen, Corynespora cassiicola. Med
Mycol. 2011;49(6):657–661.
43. Xie Z, et al. A case of phaeohyphomycosis caused
by Corynespora cassiicola infection. BMC Infect
Dis. 2018;18(1):444.
44. Yamada H, et al. Rare case of fungal keratitis
caused by Corynespora cassiicola. J Infect Chemother. 2013;19(6):1167–1169.
45. Polgreen PM, et al. CFTR heterozygotes are
at increased risk of respiratory infections: a
population-based study. Open Forum Infect Dis.
2018;5(11):ofy219.
46. Wang X, et al. Mutation in the gene responsible
for cystic fibrosis and predisposition to chronic
rhinosinusitis in the general population. JAMA.
2000;284(14):1814–1819.
47. Glass WG, et al. CCR5 deficiency increases risk
of symptomatic West Nile virus infection. J Exp
Med. 2006;203(1):35–40.
48. Lim JK, et al. Genetic deficiency of chemokine
receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis.
2008;197(2):262–265.
49. Lim JK, et al. CCR5 deficiency is a risk factor for
early clinical manifestations of West Nile virus
infection but not for viral transmission. J Infect

Dis. 2010;201(2):178–185.
50. Kerner G, et al. Homozygosity for TYK2 P1104A
underlies tuberculosis in about 1% of patients in
a cohort of European ancestry. Proc Natl Acad Sci
U S A. 2019;116(21):10430–10434.
51. MacKenzie KJ, et al. A review of Corynespora
cassiicola and its increasing relevance to tomato
in Florida. Plant Health Prog. 2018;19:303–309.
52. Brandt ME, Warnock DW. Epidemiology, clinical manifestations, and therapy of infections
caused by dematiaceous fungi. J Chemother.
2003;15(2):36–47.
53. Hsu A, et al. Immunogenetics associated
with severe coccidioidomycosis. JCI Insight.
2022;7(22):e159491.
54. Winkelstein JA, et al. Chronic granulomatous disease. Report on a national registry of 368 patients.
Medicine (Baltimore). 2000;79(3):155–169.
55. Griffiths JS, et al. A human dectin-2 deficiency
associated with invasive aspergillosis. J Infect Dis.
2021;224(7):1219–1224.
56. Langmead B, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the
human genome. Genome Biol. 2009;10(3):R25.
57. Li H, et al. The Sequence Alignment/
Map format and SAMtools. Bioinformatics.
2009;25(16):2078–2079.
58. St. Leger A, et al. An ocular commensal protects
against corneal infection by driving an Interleukin 17 response from mucosal gamma delta T
cells. Immunity. 2017;47(1):148–158.
59. Liu CM, et al. FungiQuant: a broad-coverage
fungal quantitative real-time PCR assay. BMC
Microbiol. 2012;12:255.
60. Frank T, et al. Disseminated phaeohyphomycosis
with brain abscess and biliary invasion due to
Bipolaris spp. In an immunocompetent patient.
Ann Clin Lab Sci. 2016;46(4):439–442.
61. Schweizer LA, et al. Brain abscess caused by
Cladophialophora bantiana: total remission after
full resection and short-course voriconazole
treatment. Med Mycol Case Rep. 2019;23:43–45.
62. Jelinek AG, et al. Headaches and hemiparesis in
an immunocompetent inmate. Neuropathology.
2014;34(3):314–317.
63. Singh H, et al. Curvularia fungi presenting as a
large cranial base meningioma: case report.
Neurosurgery. 2008;63(1):E177; discussion E.
64. Mody P, et al. Gram stain to the rescue: a case
report of cerebral phaeohyphomycosis by Cladophialophora bantiana in an immunocompetent
24-year-old. BMC Infect Dis. 2022;22(1):13.

J Clin Invest. 2022;132(22):e159348 https://doi.org/10.1172/JCI159348

